Corline Biomedical AB Capital Reinvestment Ratio
Corline Biomedical AB capital reinvestment ratio. Corline Biomedical AB (CLBIO) has a Capital Reinvestment Ratio of 0.16x as of June 2026, meaning it reinvests 0% of its operating cash flow (Skr122.00K) in capital expenditures (Skr19.00K). See Corline Biomedical AB (CLBIO) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Corline Biomedical AB (2023–2023)
Capital reinvestment ratio of Corline Biomedical AB from 2023 to 2023. This chart tracks Corline Biomedical AB's Capital Reinvestment Ratio across 1 annual periods. See financial agility of Corline Biomedical AB to measure the company's free cash flow as a share of total liabilities.
Corline Biomedical AB Capital Reinvestment Ratio by Year (2023–2023)
Corline Biomedical AB capital reinvestment ratio by year from 2023 to 2023. For the full cash flow conversion analysis, see Corline Biomedical AB operating cash flow efficiency.
| Year | Reinvestment Ratio | Operating CF (SEK) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 11.99x | Skr886.00K | Skr10.62 Million | — |